Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women

References

• Agnusdei D., Liu-Leage S. and Augendre-Ferrante B. (1999) Results of international clinical trials with raloxifene. Annals of Endocrinology, 60, 242–246.
   Google Scholar
• Asztalos B.F., Horvath Ky., McNamara J.R., Roheim P.S., Rubinstein J.J. and Schaefer E.J. (2002a) Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis, 164, 361–369.
   PubMed Web of Science ®Google Scholar
• Asztalos B.F., Horvath Ky., McNamara J.R., Roheim P.S., Rubinstein J.J. and Schaefer E.J. (2002b) Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. Journal of Lipid Research, 43, 1701 — 1707.
   Google Scholar
• Boyack M., Lookinland S. and Chasson S. (2002) Efficacy of raloxifene for treatment of menopause: a systematic review. Journal of the American Academy of Nurse Practice, 14, 150–165.
   PubMedGoogle Scholar
• Bryant H.U. and Dere W.H. (1998) Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proccedings of the Society of Experimental Biology and Medicine, 217, 45–52.
   PubMed Web of Science ®Google Scholar
• Colditz G.A., Willett W.C., Stampfer M.J., Rosner B.S., Speizer F.E. and Hennekens C.H. (1987) Menopause and the risk of coronary heart disease in women. New England Journal of Medicine, 316, 1105–1110.
   PubMed Web of Science ®Google Scholar
• Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W. and Gotto A.M. Jr. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Journal of the American Medical Association, 279, 1615–1622.
   Google Scholar
• Draper MW., Flowers D.E., Huster W.J. and Neild J.A. (1993) Effects of raloxifene (LY139481) HC1 on biochemical markers of bone and lipid metabolism in healthy post-menopausal women. In: Proceedings of the Fourth Interna-tional Symposium on Osteoporosis and Consensus Development Conference, edited by Christiansen C. and Riis B, pp. 119–121. Aalborg, Denmark, Handelstrykkeriet Aalborg ApS.
   Google Scholar
• Draper MW., Flowers D.E., Huster W.J., Neild J.A., Harper K.D. and Arnaud C.A. (1996) Controlled trial of raloxifene (LY139481) HC1: impact on bone turnover and serum lipid profile in healthy postmenopausal women. Journal of Bone and Mineral Research, 11, 835— 842.
   Google Scholar
• Friedewald W.T., Levy R.I. and Fredrickson S. (1972) Estimation of the concentration of the low density lipopro-tein cholesterol in plasma without use of the preparative ultracentrifuge. Clinical Chemistry, 18, 499–502.
   PubMed Web of Science ®Google Scholar
• Giral P., Bruckert E., Jacob N., Chapman M.J., Foglietti M.J. and Turpin G. (2001) Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis, 154, 421–427.
   PubMed Web of Science ®Google Scholar
• Gonbert S., Malinsky S., Sposito AC., Laouenan H., Doucet C., Chapman M.J. and Thillet J. (2002) Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis, 164, 305–311.
   PubMed Web of Science ®Google Scholar
• Hunninghake D., Insull W. Jr, Toth P., Davidson D., Donovan J.M. and Burke S.K. (2001a) Coadministration of coleseve-lam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis, 158, 407–416.
   PubMed Web of Science ®Google Scholar
• Hunninghake D., Insull W., Knopp R., Davidson M., Lohrbauer L., Jones P. and Kafonek S. (2001b) Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. American Journal of Cardiology, 88, 635— 639.
   Google Scholar
• Insull W., Kafonek S., Goldner D. and Zieve F. (2001) Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks. ASSET Investigators. American Journal of Cardiology, 87, 554— 559.
   Google Scholar
• Kakafika A., Liamis G., Elisaf M. and Mikhailidis D. (2001b) Effect of atorvastatin on serum creatinine levels. Current Medical Research Opinion, 17, 230–231.
   PubMed Web of Science ®Google Scholar
• Kakafika A., Tsimihodimos V. and Elisaf M. (2001a) Effect of atorvastatin on serum uric acid levels. Atherosclerosis, 158, 255.
   PubMed Web of Science ®Google Scholar
• Kannel W.B., Hjortland MC., Mc Namara P.M. and Gordon T. (1976) Menopause and risk of cardiovascular disease. The Framingham Study. Annals of Internal Medicine, 85, 447 — 452.
   PubMed Web of Science ®Google Scholar
• Kauffman R.F. and Bryant H.U. (1995) Selective estrogen receptor modulators. Drugs New Perspectives, 8, 531 —539.
   Google Scholar
• Lufkin E.G., Whitaker M.D., Nickelsen T., Argueta R., Caplan R.H., Knickerbocker R.K. and Riggs B.L. (1998) Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. Journal of Bone and Mineral Research, 13, 1747 — 1754.
   Google Scholar
• Nikolaidou-Politis V., Papapanagiotou A. and Kalofoutis A. (1999) Effects of hormone replacement therapy on serum lipids and phospholipids in postmenopausal women. Journal of Obstetrics and Gynecology, 19, 184— 189.
   Google Scholar
• Paolisso G., Barbagallo M., Petrella G., Ragno E., Barbieri M., Giordano M. and Varricchio M. (2000) Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin depen-dent diabetic patients. Atherosclerosis, 150, 121— 127.
   Google Scholar
• Park L. and Evans M.F. (1999) Raloxifene: designer estrogen for preventing postmenopausal osteoporosis. Canadian Fa-mily Physician, 45, 1191–1193.
   Google Scholar
• Pedersen T.R., Olsson A.G., Faergeman 0., Kjekshus J., Wedel H., Berg K., Wilhelmsen L., Haghfelt T., Thorgeirsson G., Pyorala K., Miettinen T., Christophersen B., Tobert J.A., Musliner TA. and Cook T.J. (1998) Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation, 97, 1453–1460.
   Google Scholar
• Rosenson R.S. and Tangney C.C. (1998) Anti-atherothrombo-tic properties of statins: implications for cardiovascular event reduction. Journal of the American Medical Association, 279, 1643 — 1650.
   Google Scholar
• Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Ruther-ford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R. and Braunwald E. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine, 335, 1001–1009.
   PubMed Web of Science ®Google Scholar
• Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H. and Packard C.J. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine, 333, 1301 — 1307.
   Google Scholar
• Tutor J.C., Paz J.M., Areses J. and Garcia F. (1981) Determination of high density phospholipids and its possible clinical application in the assessment of cardiovascular disease risk. Biometrica, 12, 65–69.
   Google Scholar
• Umland E.M., Rinaldi C., Parks S.M. and Boyce E.G. (1999) The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. Annals of Pharmacotherapy, 33, 1315–1328.
   PubMed Web of Science ®Google Scholar
• Walsh B.W., Kuller L.H., Wild R.A., Paul S., Farmer M., Lawrence J.B., Shah A.S. and Anderson P.W. (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. Journal of the American Medical Association, 279, 1445–1451.
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y. (1980) Determination of high-density lipopro-tein phospholipids in serum. Clinica Chimica Acta, 26, 1275–1277.
   Google Scholar
• Yang N.N., Venugopalan M., Hardikar S. and Glasebrook A. (1996) Identification of an oestrogen response element activated by metabolites of 17b-estradiol and raloxifene. Science, 273, 1222–1225.
   Google Scholar